tbuckley/cabot-search huggingface dataset:
Abstract 9440: Incidence, Charge, and Outcomes of Emergency Department Visits for Children with Single Ventricle Congenital Heart Disease from 2006-2018
Authors: Jonathan B Edelson, Monique Gardner, Austin Kilaru, Joseph Rossano, Heather M Griffis, Xuemei Zhang, Jennifer Faerber, Katie Dodds, Matthew J O'Connor, Chitra Ravishankar, Jack Rychik, David Goldberg, Laura M Mercer-rosa, Andrew C Glatz, Kimberly Lin
Journal: Circulation (2021)

Introduction: Children with single ventricle (SV) congenital heart disease have high morbidity, mortality and resource utilization when admitted to the hospital but few data exist on emergency department (ED) visits. Understanding patterns in ED encounters among children with SV may target interventions to improve outcomes. We described a national sample of SV ED visits and evaluated patient characteristics, encounters, and trends in admissions, charge, and mortality. Methods: This retrospective cohort study evaluates ED encounter level data from the 2006-2018 Nationwide Emergency Department Sample. Patients &lt; 18y with SV were identified using ICD-9/10 codes. Results: From 2006-2018, 52,512 SV ED visits were identified. Most SV ED encounters were male (61%) and &lt; 4y (65%). Patients with &gt; 1 complex chronic condition (CCC) comprised nearly 1/3 encounters (32%). Half of encounters (49%) resulted in admission or transfer, and the median inflation-adjusted charge per ED encounter was $1,939 (IQR $1,098-3,217). Nearly 1 in 50 SV ED visits resulted in death, in the ED or during the associated admission. Independent predictors of admission included age &lt;1y [OR 2.60 (2.12, 3.19)], presenting to a metropolitan teaching hospital [OR 6.31 (4.53, 8.80)], presenting with HF [OR 7.70 (5.33, 11.12)], arrythmia [OR 2.81 (1.89, 4.18)], respiratory disease [OR 5.13 (4.13, 6.43)], or sepsis [OR 8.64 (4.09, 18.26)], and the presence of 1 [OR 2.15 (1.90, 2.42)] or &gt; 2 CCC’s [OR 6.89 (5.56, 8.53)]. Independent predictors of mortality included age &lt;1y [OR 8.55 (3.28, 22.32)], presenting with HF [OR 4.97 (2.99, 8.27)], and &gt; 2 CCC’s [OR 2.19 (1.43, 3.36)]. Annual SV visits increased from 3,082 to 5,483 ( p for trend=0.003) and the inflation-adjusted charge per ED encounter increased by 50%, from $1,760 to $2,612 ( p for trend=0.002). There was no identified change in mortality ( p for trend=0.08). Conclusions: Half of ED visits of children with SV result in admission/transfer and 2% result in death. While the incidence and charges of SV ED visits increased over the years studied, there was no identified change in mortality. The high admission/transfer rate for children with SV presenting to the ED reflect a high-risk population; further attention must be given to improving their outcomes.
A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies
Authors: Elizabeth Budde, Ajay K Gopal, Won Seog Kim, Ian W. Flinn, Chan Yoon Y. Cheah, Loretta Nastoupil, Matthew J. Matasar, Catherine S. Diefenbach, Gareth P Gregory, Ibrahim Qazi, Ching-Fai Pang, Maya Leabman, Genevive Hernandez, Iris Sison, Bruce A. Keyt, Daniel Chen, Philippe Armand
Journal: Blood (2021)
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia
Authors: Claudie Bosc, Estelle Saland, Aurélie Bousard, Noémie Gadaud, Marie Sabatier, Guillaume Cognet, Thomas Farge, Emeline Boet, Mathilde Gotanègre, Nesrine Aroua, Pierre-Luc Mouchel, Nathaniel Polley, Clément Larrue, Eléonore Kaphan, Muriel Picard, Ambrine Sahal, Latifa Jarrou, Marie Tosolini, Florian Rambow, Florence Cabon, Nathalie Nicot, Laura Poillet-Perez, Yujue Wang, Xiaoyang Su, Quentin Fovez, Jérôme Kluza, Rafael José Argüello, Céline Mazzotti, Hervé Avet-Loiseau, François Vergez, Jérôme Tamburini, Jean-Jacques Fournié, Ing S. Tiong, Andrew H. Wei, Tony Kaoma, Jean-Christophe Marine, Christian Récher, Lucille Stuani, Carine Joffre, Jean-Emmanuel Sarry
Journal: Nature Cancer (2021)
Abstract 9167: Relationship Between Dietary Vitamin D Intake, Obesity, and Twenty Lipoprotein Subclasses: Results from the Kyushu and Okinawa Population Study
Authors: Hiroaki Ikezaki, Ryoko Nakashima, Norihiro Furusyo, Masumi Ai, Mitsuyo Okazaki, JUN HAYASHI, Eliana J Polisecki
Journal: Circulation (2021)

Introduction: The correlation between serum vitamin D deficiency, obesity, and various diseases has been reported, however, there were few investigations on the role of dietary vitamin D intake on obesity and dyslipidemia. Objective: To examine whether dietary vitamin D intake affects obesity and dyslipidemia. Methods: Dietary vitamin D intake amounts calculated using obtained data of food frequency questionnaire and 20 lipoprotein cholesterol and triglycerides subclasses using gel permeation high performance liquid chromatography were analyzed in 945 men and women (mean age 58.3 years, free of thyroid or chronic liver diseases and off osteoporosis, cholesterol lowering, or adrenocorticosteroid medications). Univariate and multivariate regression, and partial correlation analyses were performed to examine the associations between dietary vitamin D intake, obesity, and lipoprotein subclasses. Results: Dietary vitamin D intake had a significant negative association with body mass index in both post- and pre-menopausal women groups ( r = -0.1053 and -0.1761, P = 0.02 and 0.04, respectively). Regarding 20 lipoprotein subclasses, dietary vitamin D intake were negatively associated with very low-density lipoprotein-3 cholesterol in premenopausal women ( r = -0.2099, P =0.02) and positively associated with total high-density lipoprotein (HDL) cholesterol in men ( r = 0.1159, P = 0.04). In addition, dietary vitamin D intake also showed a marginally positive correlation with total HDL cholesterol in premenopausal women ( r = 0.1323, P = 0.13). Those association were also found in the frequency of fish intake, a major source of vitamin D in Japan. Conclusions: Our results indicate that proactive dietary vitamin D intake may help prevent or eliminate obesity and dyslipidemia.
Targeting PRMT9 Suppresses Acute Myeloid Leukemia Maintenance
Authors: Haojie Dong, Xin He, Lei Zhang, Wei Chen, Yuhui Wu, Yinghui Zhu, Hanying Wang, Wenfeng Huang, Yichun Lin, Lianjun Zhang, Dandan Zhao, Juan Du, Rui Su, Ya-Huei Kuo, Jianjun Chen, Amandeep Salhotra, Guido Marcucci, Yun Luo, Ling Li
Journal: Blood (2021)
Abstract PO-074: Identification of C-MET receptor as a therapeutic target in patient-specific tumoroid models of metastatic pancreatic adenocarcinoma allows identification of a new mode of action for its inhibitors
Authors: Liam Deems, Maria Ivanova, Cheryl Murphy, Amit Shahar, David Deems, Dmitry Shvartsman
Journal: Cancer Research (2021)

Abstract Creating patient-specific models with a high level of characterization and functionality in tumoroid modeling enables a better understanding of the disease drivers in metastatic cancers. It presents the opportunity for personalized treatment with novel therapeutic reagents in underrepresented cancers such as pancreatic ductal adenocarcinoma. Using a defined and treatment-naive patient-specific model cohort of nine patients diagnosed with pancreatic adenocarcinoma, we aimed to represent the diversity of progression grade and assay profiles. These models were tested with a panel of common, broad-range chemotherapeutic agents and characterized for genetic, proteomic, and tumoroid drug response profiles. A detailed analysis of gene expression values from the original tissue specimen, compared with cancer cultures in hypoxic, normoxic planar, and spheroid (3D) culture conditions, enabled the identification of C-MET as a critical gene that shows upregulation closely resembling the expression profile observed in the original patient biopsy and was modulated by tissue culture format. Once this potential target was identified, the pancreatic models were treated with five C-MET-targeting chemotherapeutic agents with different modes of action. Proto-oncogene receptor C-MET (HGF receptor) is a potential therapeutic target in many metastatic cancers due to its integral role in angiogenesis, proliferation, and cancer cell survival¹. We propose that these reproducible and easily scaled tumoroid models can be used to find new therapeutic targets in-vitro and provide the example of C-MET in our pancreatic cancer patient cohort. Moreover, only 3D hypoxic models closely resembled original patient tissues in their genomic expression profiles. Using these model formats, we distinguished differences between various C-MET targeting compounds and their ability to induce cell death, which correlated with their mode of action on C-MET neutralization. Identifying these targets in 3D produces new and potentially more effective drug targets where they may not have been observed solely in planar conditions with legacy cell lines. Our models of metastatic pancreatic cancer tumoroids can be readily utilized to benefit researchers and clinicians seeking new targets for patient treatment. Citation Format: Liam Deems, Maria Ivanova, Cheryl Murphy, Amit Shahar, David Deems, Dmitry Shvartsman. Identification of C-MET receptor as a therapeutic target in patient-specific tumoroid models of metastatic pancreatic adenocarcinoma allows identification of a new mode of action for its inhibitors [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-074.
Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)
Authors: Gail J. Roboz, Guillermo Sanz, Elizabeth A. Griffiths, Karen Yee, Hagop Kantarjian, Christian Recher, Michael T. Byrne, Elzbieta Patkowska, Hee-Je Kim, Xavier Thomas, Ine Moors, Wendy Stock, Arpad Illes, Pierre Fenaux, Yasushi Miyazaki, Takahiro Yamauchi, Casey L. O'Connell, Yong Hao, Harold N. Keer, Mohammad Azab, Hartmut Dohner
Journal: Blood (2021)
Coastal: A Phase 3 Study of the PI3Kδ Inhibitor Zandelisib with Rituximab (R) Versus Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Authors: Wojciech Jurczak, Pier Luigi Luigi Zinzani, David Cunningham, Michel Azoulay, Wenying Huang, Weiming Xu, Vincent Ribrag
Journal: Blood (2021)
Severe COVID-19 is associated with hyperactivation of the alternative complement pathway
Authors: Jeremy Boussier, Nader Yatim, Armance Marchal, Jérôme Hadjadj, Bruno Charbit, Carine El Sissy, Nicolas Carlier, Frédéric Pène, Luc Mouthon, Pierre-Louis Tharaux, Anne Bergeron, David M. Smadja, Frédéric Rieux-Laucat, Darragh Duffy, Solen Kernéis, Véronique Frémeaux-Bacchi, Benjamin Terrier
Journal: Journal of Allergy and Clinical Immunology (2021)
Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies
Authors: Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R. Litzow, Nebu V. Koshy, Patrick Stiff, Camille Abboud, Benjamin Tomlinson, Sunil Abhyankar, Parameswaran Hari, Zaid S. Al-Kadhimi, George L. Chen, Mitchell Sabloff, Johnnie J. Orozco, James M. Foran, Partow Kebriaei, Katarzyna Joanna Jamieson, Margarida Magalhaes Magalhaes-Silverman, Koen van Besien, Michael W. Schuster, Arjun Law, Moshe Levy, Hillard M Lazarus, Sergio A Giralt, Mark S. Berger, Jennifer A Spross, Avinash G Desai, Vijay Reddy, John M. Pagel
Journal: Blood (2021)
Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases
Authors: Ayalew Tefferi, Jaya Kittur, Faiqa Farrukh, Kebede H. Begna, Mrinal M. Patnaik, Aref Al-Kali, Michelle A Elliott, Kaaren K. Reichard, Naseema Gangat, Animesh D. Pardanani
Journal: Blood (2021)
Effect of Hydroxyurea Therapy on the Incidence of Infections in Ugandan Children with Sickle Cell Anaemia
Authors: Ruth Namazzi, Andrea L. Conroy, Caitlin Bond, Micheal J. Goings, Dibyadyuti Datta, Russell E. Ware, Jeong Hoon Jang, Chandy C. John, Robert O. Opoka
Journal: Blood (2021)
Development and Validation of [18f](2 <i>S</i>,4 <i>R</i>)-4-Fluoroglutamine in Multiple Myeloma Mouse Models
Authors: Denise Toscani, Silvia Valtorta, Martina Chiu, Andrea Sartori, Angela Coliva, Arianna Brevi, Giuseppe Taurino, Matteo Grioni, Vincenzo Raimondi, Jessica Burroughs-Garcia, Paola Storti, Livia Ruffini, Federica Vacondio, Franca Zanardi, Matteo Bellone, Rosa Maria Moresco, Ovidio Bussolati, Nicola Giuliani
Journal: Blood (2021)
The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes
Authors: Eugene Brailovski, Qing Li, Ning Liu, Brian Leber, Dina Khalaf, Mitchell Sabloff, Grace Christou, Karen Yee, Lisa Chodirker, Anne Parmentier, Mohammed Siddiqui, Alexandre Mamedov, Liying Zhang, Ying Liu, Craig C. Earle, Matthew Cheung, Nicole Mittman, Rena J. Buckstein, Lee Mozessohn
Journal: Blood (2021)
Magnetic Gold Nanoparticles with Idealized Coating for Enhanced Point‐Of‐Care Sensing
Authors: Isabel Gessner, Jin‐Ho Park, Hsing‐Ying Lin, Hakho Lee, Ralph Weissleder
Journal: Advanced Healthcare Materials (2021)

Magnetic nanoparticles with hybrid sensing functions are in wide use for bioseparation, sensing, and in vivo imaging. Yet, nonspecific protein adsorption to the particle surface continues to present a technical challenge and diminishes the theoretical protein detection capabilities. Here, a magneto-plasmonic nanoparticle synthesis is developed that minimizes nonspecific protein adsorption. Building on the success of zwitterionic polymers, a highly stable and anergic nanomaterial, magnetic gold nanoparticles with idealized coating (MAGIC) is obtained with significantly lower serum protein adsorption compared to control nanoparticles coated with commonly used polymers (polyethylene glycol, polyethylenimine, or polyallylamine hydrochloride). MAGIC nanoparticles are able to sense specific bladder cancer biomarkers at low levels and in the presence of other proteins. This strategy may find wide spread applications for in vitro and in vivo sensing as well as isolations.
Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study
Authors: Nilanjan Ghosh, William Townsend, Michael Dickinson, Max Topp, Monica Tani, Armando Santoro, Michael Crump, Franck Morschhauser, Steven Le Gouill, Amitkumar Mehta, Anesh Panchal, Chun Wu, Martin Barrett, Kathryn Humphrey, Naseer Qayum, Martin Hutchings
Journal: Blood (2021)
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study
Authors: Fangwen Zou, David Faleck, Anusha Thomas, Jessica Harris, Deepika Satish, Xuemei Wang, Aline Charabaty, Marc S Ernstoff, Isabella C Glitza Oliva, Stephen Hanauer, Jennifer McQuade, Michel Obeid, Amishi Shah, David M Richards, Elad Sharon, Jedd Wolchok, John Thompson, Yinghong Wang
Journal: Journal for ImmunoTherapy of Cancer (2021)

Current treatment guidelines for immune-mediated diarrhea and colitis (IMDC) recommend steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) for refractory cases. We aimed to compare the efficacy of these two SITs and their impact on cancer outcomes.We performed a two-center, retrospective observational cohort study of patients with IMDC who received SITs following steroids from 2016 to 2020. Patients' demographic, clinical, and overall survival data were collected and analyzed.A total of 184 patients (62 vedolizumab, 94 infliximab, 28 combined sequentially) were included. The efficacy of achieving clinical remission of IMDC was similar (89% vs 88%, p=0.79) between the two groups. Compared with the infliximab group, the vedolizumab group had a shorter steroid exposure (35 vs 50 days, p<0.001), fewer hospitalizations (16% vs 28%, p=0.005), and a shorter hospital stay (median 10.5 vs 13.5 days, p=0.043), but a longer time to clinical response (17.5 vs 13 days, p=0.012). Longer durations of immune checkpoint inhibitors treatment (OR 1.01, p=0.004) and steroid use (OR 1.02, p=0.043), and infliximab use alone (OR 2.51, p=0.039) were associated with higher IMDC recurrence. Furthermore, ≥3 doses of SIT (p=0.011), and fewer steroid tapering attempts (p=0.012) were associated with favorable overall survival.Treatment with vedolizumab as compared with infliximab for IMDC led to comparable IMDC response rates, shorter duration of steroid use, fewer hospitalizations, and lower IMDC recurrence, though with slightly longer time to IMDC response. Higher number of SIT doses was associated with better survival outcome, while more steroid exposure resulted in worse patient outcomes.
Isogenic MDS-RS Patient-Derived iPSCs Define the Mis-Spliced Transcript Repertoire and Chromatin Landscape of SF3B1-Mutant Hematopoietic Stem/Progenitor Cells
Authors: George Asimomitis, André G. Deslauriers, Andriana G. Kotini, Elsa Bernard, Davide Esposito, Malgorzata Olszewska, Nikolaos Spyrou, Juan Arango Ossa, Teresa Mortera-Blanco, Richard Koche, Stuart Aaronson, Eva Hellström-Lindberg, Elli Papaemmanuil, Eirini P. Papapetrou
Journal: Blood (2021)
Randomized Controlled Trial of the Efficacy and Safety of Deferiprone: Subgroup Analysis of Pediatric Patients in Iron-Overloaded Patients with Sickle Cell Disease and Other Anemias
Authors: Mona Hamdy, Amal El-Beshlawy, Fatma Soliman Elsayed Ebeid, Janet L. Kwiatkowski, Julie Kanter, Baba PD Inusa, Suzan Williams, David Lee, Noemi T Temin, Caroline Fradette, Fernando Tricta, Mohsen Saleh Elalfy
Journal: Blood (2021)
Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation
Authors: Marta Sobas, Javier Martinez Elicegui, Angela Villaverde Ramiro, Teresa González, Alberto Hernandez-Sanchez, Raúl Azibeiro Melchor, Axel Benner, Eric Sträng, Castellani Gastone, Caroline A. Heckman, Ana Heredia Casanoves, Jurjen Versluis, María Abáigar, Laura Jamilis, Peter JM Valk, Klaus H. Metzeler, Rosa Ayala, Joaquin Martinez Lopez, Hervé Dombret, Jorge Sierra, Claude Preudomme, Frederick Damm, Ken I Mills, Jiří Mayer, Christian Thiede, Maria Teresa Voso, Sergio Amadori, Guillermo Sanz, Frederico Calado, Konstanze Döhner, Verena I Gaidzik, Michael Heuser, Torsten Haferlach, Amin T. Turki, Dirk Reinhardt, Rubén Villoria Medina, Michel Van Speybroeck, Renate Schulze-Rath, John E Butler, Brian J.P Huntly, Hartmut Dohner, Gert J. Ossenkoppele, Lars Bullinger, Jesus Maria Hernández-Rivas
Journal: Blood (2021)
Response to Extracorporeal Photopheresis in Patients with Cutaneous T-Cell Lymphoma: A Retrospective Medical Chart Review
Authors: Michael Girardi, Amy G Johnson, Kacie Carlson, Xingyue Huang, Shelby Corman, Patrick Edmundson, Hrishikesh P Kale, Nifasha Rusibamayila, Francine M. Foss
Journal: Blood (2021)
Idarucizumab for Reversal of Dabigatran: Multicenter Real-World Experience
Authors: Paola Alejandra Barzallo Burbano, Mar Meijón, Nuria Revilla Calvo, María Jesús Blanco Bañares, Begoña Fernández, Ramón Rodríguez-González, María Elena Sola Aparicio, Belén Rosado Sierra, Susana Asenjo Correa, Isabel Gutiérrez, María Pilar Llamas Sillero, José L. Díez-Martín, Gloria Pérez-Rus, Cristina Pascual Izquierdo
Journal: Blood (2021)
Trial in Progress: Asciminib in Monotherapy 4 CML (AIM4CML), a Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase without or with T315I Mutations
Authors: David Andorsky, Sarah Tomassetti, Yehuda E. Deutsch, E Randolph Broun, Ghayas C. Issa, Moshe Y. Levy, Michael W. Deininger, Rodrigo Maegawa, Alok Shrestha, Michael J. Mauro
Journal: Blood (2021)
Saving Lives with Pride: Development and Evaluation of Multimedia Resources to Engage Gay, Bisexual, and Queer Men in Canada As Stem Cell Donors
Authors: Rupal Hatkar, Lauren Sano, Natalie DeGurse, Elena Kum, Michelle Ho, Bonnie Lu, Brady Park, Joel Koette, Rana Kandel, Gabriele Jagelaviciute, Warren Fingrut
Journal: Blood (2021)
Covid-19: Trial of experimental “covid cure” is among worst medical ethics violations in Brazil’s history, says regulator
Authors: Luke Taylor
Journal: BMJ (2021)

During the Early Medieval period, the Carpathian Basin witnessed significant demographic shifts, notably under Avar dominance for approximately 250 years, followed by the settlement of early Hungarians in the region during the late 9th century CE. This study presents the genetic analysis of 296
Proteomic Analysis of Human Lung Development
Authors: Geremy Clair, Lisa M. Bramer, Ravi Misra, Matthew D. McGraw, Soumyaroop Bhattacharya, Joseph A. Kitzmiller, Song Feng, Vincent G. Danna, Gautam Bandyopadhyay, Harsh Bhotika, Heidie L. Huyck, Gail H. Deutsch, Thomas J. Mariani, James P. Carson, Jeffrey A. Whitsett, Gloria S. Pryhuber, Joshua N. Adkins, Charles Ansong
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

Rationale: The current understanding of human lung development derives mostly from animal studies. Although transcript-level studies have analyzed human donor tissue to identify genes expressed during normal human lung development, protein-level analysis that would enable the generation of new hypotheses on the processes involved in pulmonary development are lacking. Objectives: To define the temporal dynamic of protein expression during human lung development. Methods: We performed proteomics analysis of human lungs at 10 distinct times from birth to 8 years to identify the molecular networks mediating postnatal lung maturation. Measurements and Main Results: We identified 8,938 proteins providing a comprehensive view of the developing human lung proteome. The analysis of the data supports the existence of distinct molecular substages of alveolar development and predicted the age of independent human lung samples, and extensive remodeling of the lung proteome occurred during postnatal development. Evidence of post-transcriptional control was identified in early postnatal development. An extensive extracellular matrix remodeling was supported by changes in the proteome during alveologenesis. The concept of maturation of the immune system as an inherent part of normal lung development was substantiated by flow cytometry and transcriptomics. Conclusions: This study provides the first in-depth characterization of the human lung proteome during development, providing a unique proteomic resource freely accessible at Lungmap.net. The data support the extensive remodeling of the lung proteome during development, the existence of molecular substages of alveologenesis, and evidence of post-transcriptional control in early postnatal development.
Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)
Authors: John F. Seymour, Jenny Qun Wu, Relja Popovic, Barbara Eichhorst, Peter Hillmen, Thomas J. Kipps, Anton W. Langerak, Carolyn Owen, Julie Dubois, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Fengjiao Dunbar, Yanwen Jiang, Brenda Chyla, Michelle Boyer, Maria Thadani-Mulero, Marcus Lefebure, Rosemary Harrup, Arnon P. Kater
Journal: Blood (2021)
Clinical Features and Long-Term Outcomes in a Molecularly-Annotated Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms
Authors: James T. England, Rouslan Kotchetkov, Hubert Tsui, Jose-Mario Capo-Chichi, Andrea Arruda, Sarah Malik, Verna Cheung, Taylor Nye, Hassan Sibai, Vikas Gupta, Dawn Maze
Journal: Blood (2021)